<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1140" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1140/" /><meta name="ncbi_pagename" content="Spinocerebellar Ataxia Type 6 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Spinocerebellar Ataxia Type 6 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Spinocerebellar Ataxia Type 6" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/11/21" /><meta name="citation_author" content="Hannah L Casey" /><meta name="citation_author" content="Christopher M Gomez" /><meta name="citation_pmid" content="20301319" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1140/" /><meta name="citation_keywords" content="SCA6" /><meta name="citation_keywords" content="SCA6" /><meta name="citation_keywords" content="Voltage-dependent P/Q-type calcium channel subunit alpha-1A" /><meta name="citation_keywords" content="CACNA1A" /><meta name="citation_keywords" content="Spinocerebellar Ataxia Type 6" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Spinocerebellar Ataxia Type 6" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Hannah L Casey" /><meta name="DC.Contributor" content="Christopher M Gomez" /><meta name="DC.Date" content="2019/11/21" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1140/" /><meta name="description" content="Spinocerebellar ataxia type 6 (SCA6) is characterized by adult-onset, slowly progressive cerebellar ataxia, dysarthria, and nystagmus. The age of onset ranges from 19 to 73 years; mean age of onset is between 43 and 52 years. Initial symptoms are gait unsteadiness, stumbling, and imbalance (in ~90%) and dysarthria (in ~10%). Eventually all persons have gait ataxia, upper-limb incoordination, intention tremor, and dysarthria. Dysphagia and choking are common. Visual disturbances may result from diplopia, difficulty fixating on moving objects, horizontal gaze-evoked nystagmus, and vertical nystagmus. Hyperreflexia and extensor plantar responses occur in up to 40%-50%. Basal ganglia signs, including dystonia and blepharospasm, occur in up to 25%. Mentation is generally preserved." /><meta name="og:title" content="Spinocerebellar Ataxia Type 6" /><meta name="og:type" content="book" /><meta name="og:description" content="Spinocerebellar ataxia type 6 (SCA6) is characterized by adult-onset, slowly progressive cerebellar ataxia, dysarthria, and nystagmus. The age of onset ranges from 19 to 73 years; mean age of onset is between 43 and 52 years. Initial symptoms are gait unsteadiness, stumbling, and imbalance (in ~90%) and dysarthria (in ~10%). Eventually all persons have gait ataxia, upper-limb incoordination, intention tremor, and dysarthria. Dysphagia and choking are common. Visual disturbances may result from diplopia, difficulty fixating on moving objects, horizontal gaze-evoked nystagmus, and vertical nystagmus. Hyperreflexia and extensor plantar responses occur in up to 40%-50%. Basal ganglia signs, including dystonia and blepharospasm, occur in up to 25%. Mentation is generally preserved." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1140/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/sca6/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1140/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B8FB8E04104310000000000030001.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1140_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1140_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sca3/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sca7/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1140_"><span class="title" itemprop="name">Spinocerebellar Ataxia Type 6</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: SCA6</div><p class="contrib-group"><span itemprop="author">Hannah L Casey</span>, BS and <span itemprop="author">Christopher M Gomez</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1140_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1140_ai__"><div class="contrib half_rhythm"><span itemprop="author">Hannah L Casey</span>, BS<div class="affiliation small">Department of Neurology<br />University of Chicago<br />Chicago, Illinois<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.ogacihcu.dsb.ygoloruen@yesachannah" class="oemail">ude.ogacihcu.dsb.ygoloruen@yesachannah</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Christopher M Gomez</span>, MD, PhD<div class="affiliation small">Department of Neurology<br />University of Chicago<br />Chicago, Illinois<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.ogacihcu.dsb.ygoloruen@zemogc" class="oemail">ude.ogacihcu.dsb.ygoloruen@zemogc</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">October 23, 1998</span>; Last Update: <span itemprop="dateModified">November 21, 2019</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="sca6.Summary" itemprop="description"><h2 id="_sca6_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Spinocerebellar ataxia type 6 (SCA6) is characterized by adult-onset, slowly progressive cerebellar ataxia, dysarthria, and nystagmus. The age of onset ranges from 19 to 73 years; mean age of onset is between 43 and 52 years. Initial symptoms are gait unsteadiness, stumbling, and imbalance (in ~90%) and dysarthria (in ~10%). Eventually all persons have gait ataxia, upper-limb incoordination, intention tremor, and dysarthria. Dysphagia and choking are common. Visual disturbances may result from diplopia, difficulty fixating on moving objects, horizontal gaze-evoked nystagmus, and vertical nystagmus. Hyperreflexia and extensor plantar responses occur in up to 40%-50%. Basal ganglia signs, including dystonia and blepharospasm, occur in up to 25%. Mentation is generally preserved.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of SCA6 rests on the use of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to detect an abnormal CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion in <i>CACNA1A</i>. Affected individuals have 20 to 33 CAG repeats.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Acetazolamide may eliminate episodes of ataxia; canes, walking sticks, and walkers to prevent falling; home modifications for safety and convenience; weighted eating utensils and dressing hooks; physical therapy and exercises enhancing balance and core strength; vitamin supplements particularly if caloric intake is reduced; feeding recommendations as per feeding therapist / occupational therapist; weight control, as obesity exacerbates ambulation and mobility problems; vestibular symptoms may be managed with medications including diphenhydramine, baclofen, and gabapentin. 4-aminopyridine may be helpful with vestibular symptoms and to suppress nystagmus; refractive or surgical management per ophthalmologist for diplopia; speech therapy and communication devices for dysarthria; clonazepam for REM sleep disorders; continuous positive airway pressure for sleep apnea.</p><p><i>Surveillance:</i> Annual or semiannual evaluation by a neurologist; driving ability should be assessed by professionals periodically. Annual consultations with a physiatrist and physical and/or occupational therapist; review need for walking aid(s) and home adaptations. Nutrition evaluation, video esophagram, and feeding assessments as needed. Ophthalmology and/or optometry evaluation as needed for prisms or surgery.</p><p><i>Agents/circumstances to avoid:</i> Sedative hypnotics (ethanol or certain medications) that increase incoordination.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>SCA6 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Offspring of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual have a 50% chance of inheriting an abnormal CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion in <i>CACNA1A</i>. Once a <i>CACNA1A</i> CAG repeat expansion has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> for SCA6 are possible.</p></div></div><div id="sca6.Diagnosis"><h2 id="_sca6_Diagnosis_">Diagnosis</h2><p>Formal diagnostic criteria for spinocerebellar ataxia type 6 (SCA6) have not been established.</p><div id="sca6.Suggestive_Findings"><h3>Suggestive Findings</h3><p>SCA6 <b>should be suspected</b> in individuals with the following clinical and imaging findings:</p><ul><li class="half_rhythm"><div><b>Clinical findings</b> include adult-onset, slowly progressive cerebellar ataxia; dysarthria; and nystagmus.</div></li><li class="half_rhythm"><div><b>Imaging findings.</b> Atrophy of the cerebellum, most pronounced in the cerebellar vermis, is present in symptomatic individuals with SCA6 [<a class="bk_pop" href="#sca6.REF.butteriss.2005.694">Butteriss et al 2005</a>, <a class="bk_pop" href="#sca6.REF.lukas.2011.123">Lukas et al 2011</a>].</div></li></ul></div><div id="sca6.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of SCA6 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> CAG repeat expansion in <i>CACNA1A</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1140/table/sca6.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figsca6Tmoleculargenetictestingusedin" rid-ob="figobsca6Tmoleculargenetictestingusedin">Table 1</a>).</p><p><b>Allele sizes</b></p><ul><li class="half_rhythm"><div><b>Normal alleles.</b> &#x02264;18 CAG repeats [<a class="bk_pop" href="#sca6.REF.shizuka.1998.85">Shizuka et al 1998</a>]</div></li><li class="half_rhythm"><div><b>Full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles.</b> 20-33 CAG repeats [<a class="bk_pop" href="#sca6.REF.jodice.1997.1973">Jodice et al 1997</a>, <a class="bk_pop" href="#sca6.REF.yabe.1998.89">Yabe et al 1998</a>]. Asymptomatic individuals bearing an expansion of (CAG)<sub>20</sub> or greater are expected to develop symptoms at some time in their life. The most common pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has 22 CAG repeats.</div></li><li class="half_rhythm"><div><b>Alleles of questionable significance.</b> 19 CAG repeats. The clinical significance of alleles with 19 CAG repeats is unclear because alleles of this size have been documented in the following:</div><ul><li class="half_rhythm"><div>Meiotic expansion of a 19-CAG repeat <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> into the known pathogenic range [<a class="bk_pop" href="#sca6.REF.mariotti.2001.1502">Mariotti et al 2001</a>, <a class="bk_pop" href="#sca6.REF.shimazaki.2001.101">Shimazaki et al 2001</a>]. In this instance, the allele is considered an "intermediate allele" or a "mutable normal allele" (i.e., it is not disease causing but predisposes to expansion into the abnormal range).</div></li><li class="half_rhythm"><div>Elderly asymptomatic individuals [<a class="bk_pop" href="#sca6.REF.ishikawa.1997.336">Ishikawa et al 1997</a>, <a class="bk_pop" href="#sca6.REF.mariotti.2001.1502">Mariotti et al 2001</a>]</div></li><li class="half_rhythm"><div>An individual with atypical features of SCA6 [<a class="bk_pop" href="#sca6.REF.katayama.2000.711">Katayama et al 2000</a>]</div></li><li class="half_rhythm"><div>An ataxic individual <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the 19-CAG repeat <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#sca6.REF.mariotti.2001.1502">Mariotti et al 2001</a>]</div></li></ul></li></ul><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Targeted analysis for a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>CACNA1A</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with more than 18 repeats should be performed first.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>An ataxia <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>CACNA1A</i> CAG-repeat analysis and other genes of interest (see <a href="#sca6.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="sca6.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Spinocerebellar Ataxia Type 6</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1140/table/sca6.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca6.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sca6.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_sca6.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_sca6.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_sca6.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CACNA1A</i></td><td headers="hd_h_sca6.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>3</sup></td><td headers="hd_h_sca6.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="sca6.TF.1.1"><p class="no_margin">See <a href="/books/NBK1140/#sca6.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="sca6.TF.1.2"><p class="no_margin">See <a href="#sca6.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="sca6.TF.1.3"><p class="no_margin"><a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> amplification can detect CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansions up to ~100 repeats.</p></div></dd></dl></div></div></div></div></div><div id="sca6.Clinical_Characteristics"><h2 id="_sca6_Clinical_Characteristics_">Clinical Characteristics</h2><div id="sca6.Clinical_Description"><h3>Clinical Description</h3><p>To date, fewer than 10,000 individuals with spinocerebellar ataxia type 6 (SCA6) have been identified. The following description of the phenotypic features associated with this condition is based on these reported individuals.</p><div id="sca6.T.features_of_spinocerebellar_ataxi" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Features of Spinocerebellar Ataxia Type 6</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1140/table/sca6.T.features_of_spinocerebellar_ataxi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca6.T.features_of_spinocerebellar_ataxi_lrgtbl__"><table><thead><tr><th id="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feature</th><th id="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of Persons with Feature</th></tr></thead><tbody><tr><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gait unsteadiness, upper-limb incoordination, intention tremor, &#x00026; dysarthria</td><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr><tr><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Horizontal gaze-evoked nystagmus</td><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%-100%</td></tr><tr><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vertical nystagmus</td><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">65%-83%</td></tr><tr><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Diplopia</td><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td></tr><tr><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hyperreflexia &#x00026; extensor plantar responses</td><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%-50%</td></tr><tr><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dystonia &#x00026; blepharospasm</td><td headers="hd_h_sca6.T.features_of_spinocerebellar_ataxi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;25%</td></tr></tbody></table></div></div><p>SCA6 is characterized by adult-onset, slowly progressive cerebellar ataxia, dysarthria, and nystagmus. The range in age of onset is from 19 to 73 years. The mean age of onset is between 43 and 52 years. Age of onset and clinical picture vary even within the same family; sibs with the same size <a class="def" href="/books/n/gene/glossary/def-item/full-penetrance-allele/">full-penetrance allele</a> may differ in age of onset by as much as 12 years, or exhibit, at least initially, an episodic course [<a class="bk_pop" href="#sca6.REF.gomez.1997.933">Gomez et al 1997</a>, <a class="bk_pop" href="#sca6.REF.jodice.1997.1973">Jodice et al 1997</a>].</p><p>Initial symptoms are gait unsteadiness, stumbling, and imbalance in approximately 90% of individuals; the remainder present with dysarthria. Symptoms progress slowly, and eventually all persons have gait ataxia, upper-limb incoordination, intention tremor, and dysarthria. Dysphagia and choking are common.</p><p>Diplopia occurs in approximately 50% of individuals. Others experience visual disturbances related to difficulty fixating on moving objects, as well as horizontal gaze-evoked nystagmus (70%-100%) [<a class="bk_pop" href="#sca6.REF.moscovich.2015.16">Moscovich et al 2015</a>] and vertical nystagmus (65%-83%), which is observed in fewer than 10% of those with other forms of SCA [<a class="bk_pop" href="#sca6.REF.yabe.2003.440">Yabe et al 2003</a>]. Other eye movement abnormalities, including periodic alternating nystagmus and rebound nystagmus, have also been described [<a class="bk_pop" href="#sca6.REF.hashimoto.2003.1201">Hashimoto et al 2003</a>].</p><p>Hyperreflexia and extensor plantar responses occur in up to 40%-50% of individuals with SCA6.</p><p>Basal ganglia signs, such as dystonia and blepharospasm, are noted in up to 25% of individuals.</p><p>Mentation is generally preserved. Formal neuropsychological testing in one series revealed no significant cognitive deficits [<a class="bk_pop" href="#sca6.REF.globas.2003.1482">Globas et al 2003</a>].</p><p>Individuals with SCA6 do not have sensory complaints, restless legs, stiffness, migraine, primary visual disturbances, or muscle atrophy.</p><p>Life span is not shortened.</p><p><b>Other.</b> REM sleep behavior disorders are rarely reported [<a class="bk_pop" href="#sca6.REF.boesch.2006.529">Boesch et al 2006</a>, <a class="bk_pop" href="#sca6.REF.howell.2006.1430">Howell et al 2006</a>].</p><p><b>Pregnancy.</b> The severity of the disease increases during pregnancy. No effect on the viability of the fetus has been reported.</p><p><b>Neuropathology.</b> Neuropathologic studies in individuals with SCA6 have demonstrated either selective Purkinje cell degeneration or a combined degeneration of Purkinje cells and granule cells [<a class="bk_pop" href="#sca6.REF.gomez.1997.933">Gomez et al 1997</a>, <a class="bk_pop" href="#sca6.REF.sasaki.1998.199">Sasaki et al 1998</a>].</p></div><div id="sca6.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b>Heterozygous individuals.</b> Although the age of onset of symptoms of SCA6 correlates inversely with the length of the expanded CAG repeat, the same broad range of onset has been noted for individuals with 22 CAG repeats, the most common disease-associated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#sca6.REF.gomez.1997.933">Gomez et al 1997</a>, <a class="bk_pop" href="#sca6.REF.sch_ls.1998.67">Sch&#x000f6;ls et al 1998</a>]. In the few individuals with (CAG)<sub>30</sub> or (CAG)<sub>33</sub>, onset has been later than in individuals with (CAG)<sub>22</sub> and (CAG)<sub>23</sub> [<a class="bk_pop" href="#sca6.REF.matsuyama.1997.1283">Matsuyama et al 1997</a>, <a class="bk_pop" href="#sca6.REF.yabe.1998.89">Yabe et al 1998</a>]. A recent retrospective study showed even closer correlation of age of onset with the sum of the two allele sizes [<a class="bk_pop" href="#sca6.REF.takahashi.2004.256">Takahashi et al 2004</a>].</p><p><b>Homozygous individuals.</b> Several individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for an abnormal expansion in <i>CACNA1A</i> have been reported [<a class="bk_pop" href="#sca6.REF.geschwind.1997a.1247">Geschwind et al 1997a</a>, <a class="bk_pop" href="#sca6.REF.ikeuchi.1997.879">Ikeuchi et al 1997</a>, <a class="bk_pop" href="#sca6.REF.matsuyama.1997.1283">Matsuyama et al 1997</a>]. In three individuals, the onset was earlier and symptoms appeared to be slightly more severe than in individuals who were <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> [<a class="bk_pop" href="#sca6.REF.geschwind.1997a.1247">Geschwind et al 1997a</a>, <a class="bk_pop" href="#sca6.REF.ikeuchi.1997.879">Ikeuchi et al 1997</a>]; in one study age of onset correlated with the sum of two <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> sizes [<a class="bk_pop" href="#sca6.REF.takahashi.2004.256">Takahashi et al 2004</a>].</p></div><div id="sca6.Penetrance"><h3>Penetrance</h3><p>Penetrance is nearly 100%, although symptoms may not appear until the seventh decade.</p></div><div id="sca6.Anticipation"><h3>Anticipation</h3><p>Expansions of <i>CACNA1A</i> are not commonly observed in transmission from parent to child; thus, <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> has not been observed in SCA6. The age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be predicted by the family history or CAG repeat size.</p></div><div id="sca6.Nomenclature"><h3>Nomenclature</h3><p>Hereditary forms of ataxia once known as Holmes type of cerebellar cortical degeneration, and later as <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> cerebellar ataxia type III (pure cerebellar ataxia), may have included SCA6.</p></div><div id="sca6.Prevalence"><h3>Prevalence</h3><p>The prevalence of SCA6 appears to vary by geographic area, presumably relating to founder effects. Estimated as the fraction of all kindreds with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> spinocerebellar ataxia, rates for SCA6 are 1%-2% in Spain and France, 3% in China, 12% in the US, 13% in Germany, and 31% in Japan.</p><p>The overall prevalence of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> ataxia is estimated at 1:100,000, and the prevalence of SCA6 at 0.02:100,000 to 0.31:100,000 [<a class="bk_pop" href="#sca6.REF.geschwind.1997a.1247">Geschwind et al 1997a</a>, <a class="bk_pop" href="#sca6.REF.ikeuchi.1997.879">Ikeuchi et al 1997</a>, <a class="bk_pop" href="#sca6.REF.matsumura.1997.1238">Matsumura et al 1997</a>, <a class="bk_pop" href="#sca6.REF.matsuyama.1997.1283">Matsuyama et al 1997</a>, <a class="bk_pop" href="#sca6.REF.riess.1997.1289">Riess et al 1997</a>, <a class="bk_pop" href="#sca6.REF.stevanin.1997.1243">Stevanin et al 1997</a>, <a class="bk_pop" href="#sca6.REF.sch_ls.1998.67">Sch&#x000f6;ls et al 1998</a>, <a class="bk_pop" href="#sca6.REF.pujana.1999.516">Pujana et al 1999</a>, <a class="bk_pop" href="#sca6.REF.jiang.2005.25">Jiang et al 2005</a>]. In the most accurate assessment to date, <a class="bk_pop" href="#sca6.REF.craig.2004.752">Craig et al [2004]</a> used a large collection of non-selected samples of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA; they estimated the prevalence of the pathogenic <i>CACNA1A</i> expansion in the United Kingdom at 5:100,000.</p><p>The frequency of <i>CACNA1A</i> expansions among individuals with ataxia and no known family history of ataxia was determined to be 5% in one study [<a class="bk_pop" href="#sca6.REF.sch_ls.1998.67">Sch&#x000f6;ls et al 1998</a>] and 43% in another [<a class="bk_pop" href="#sca6.REF.geschwind.1997a.1247">Geschwind et al 1997a</a>]; however, premature death of parents may have hindered complete ascertainment (see <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>).</p></div></div><div id="sca6.Genetically_Related_Allelic_Disorde"><h2 id="_sca6_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>Heterozygous <i>CACNA1A</i> pathogenic variants are also known to be associated with episodic ataxia type 2, progressive cerebellar ataxia, and <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hemiplegic migraine (see <a class="figpopup" href="/books/NBK1140/table/sca6.T.allelic_autosomal_dominant_disord/?report=objectonly" target="object" rid-figpopup="figsca6Tallelicautosomaldominantdisord" rid-ob="figobsca6Tallelicautosomaldominantdisord">Table 3</a>).</p><div id="sca6.T.allelic_autosomal_dominant_disord" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Allelic Autosomal Dominant Disorders to Consider in the Differential Diagnosis of Spinocerebellar Ataxia Type 6</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1140/table/sca6.T.allelic_autosomal_dominant_disord/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca6.T.allelic_autosomal_dominant_disord_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Associated <i>CACNA1A</i> Pathogenic Variant(s)</th><th id="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Characteristics</th><th id="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Overlap w/SCA6</th></tr></thead><tbody><tr><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ea2/">Episodic ataxia type 2</a> (EA2)</td><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Missense, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a>, frameshift,<br />&#x00026; <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>/<br />multiexon deletions</td><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Onset typically in childhood or early adolescence</div></li><li class="half_rhythm"><div>Attacks of ataxia, vertigo, &#x00026; nausea lasting hrs to days</div></li><li class="half_rhythm"><div>Attacks can be assoc w/dysarthria, diplopia, tinnitus, dystonia, hemiplegia, &#x00026; headache.</div></li><li class="half_rhythm"><div>Between attacks, individuals may initially be normal but eventually develop interictal findings incl nystagmus &#x00026; ataxia.</div></li><li class="half_rhythm"><div>After years of episodic ataxia, a condition of interictal ataxia indistinguishable from SCA6 may develop.&#x000a0;<sup>1</sup></div></li></ul>
</td><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Individuals w/SCA6 may present w/EA.&#x000a0;<sup>2</sup></div></li><li class="half_rhythm"><div>1 family w/a <i>CACNA1A</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant had both SCA6 &#x00026; EA2 phenotypes.&#x000a0;<sup>3</sup></div></li><li class="half_rhythm"><div>2 families w/a <i>CACNA1A</i> CAG repeat expansion had both SCA6 &#x00026; EA2 phenotypes.&#x000a0;<sup>4</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive cerebellar ataxia</td><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Missense variants incl p.Gly293Arg in the P loop of the 1st <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, p.Ala454Thr in the I-II loop, &#x00026; p.Arg1664Gln.&#x000a0;<sup>5</sup></td><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Severe progressive ataxia</div></li><li class="half_rhythm"><div>Cerebellar atrophy</div></li></ul>
</td><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Very similar <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> to that of SCA6 assoc w/CAG repeat expansions&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/fhm/">Familial hemiplegic migraine</a> (FHM)&#x000a0;<sup>7</sup></td><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Missense, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>,<br />&#x00026; <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>/<br />multiexon deletions</td><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Aura of hemiplegia assoc w/at least 1 other aura symptom (e.g., hemianopsia, hemisensory deficit, aphasia) followed by moderate-to-severe headache</div></li><li class="half_rhythm"><div>Coma &#x00026; seizures (can be triggered by minor head injury or angiography)</div></li><li class="half_rhythm"><div>Trauma-triggered delayed cerebral edema&#x000a0;<sup>8</sup></div></li></ul>
</td><td headers="hd_h_sca6.T.allelic_autosomal_dominant_disord_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>In a family w/EA2, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> members also had hemiplegia &#x00026; 1 affected member had migraine during episodes of ataxia.&#x000a0;<sup>9</sup></div></li><li class="half_rhythm"><div>In a family w/a <i>CACNA1A</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant, phenotypes of both SCA6 &#x00026; FHM were observed.&#x000a0;<sup>10</sup></div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">EA = episodic ataxia</p></div></dd><dt>1. </dt><dd><div id="sca6.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#sca6.REF.baloh.1997.8">Baloh et al [1997]</a></p></div></dd><dt>2. </dt><dd><div id="sca6.TF.3.2"><p class="no_margin">In one study, up to 33% of individuals with &#x02265;21 CAG repeats in <i>CACNA1A</i> had episodic features prominent enough to warrant the diagnosis of EA2 [<a class="bk_pop" href="#sca6.REF.geschwind.1997a.1247">Geschwind et al 1997a</a>]. In one family with a CAG repeat expansion, some members had episodic ataxia and others had progressive ataxia; in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> members the abnormal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> had 23 CAG repeats [<a class="bk_pop" href="#sca6.REF.jodice.1997.1973">Jodice et al 1997</a>].</p></div></dd><dt>3. </dt><dd><div id="sca6.TF.3.3"><p class="no_margin"><a class="bk_pop" href="#sca6.REF.cricchi.2007.69">Cricchi et al [2007]</a></p></div></dd><dt>4. </dt><dd><div id="sca6.TF.3.4"><p class="no_margin"><a class="bk_pop" href="#sca6.REF.jodice.1997.1973">Jodice et al [1997]</a></p></div></dd><dt>5. </dt><dd><div id="sca6.TF.3.5"><p class="no_margin">As these pathogenic variants do not act through nuclear <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> of an expanded polyglutamine tract in the C terminus, the disease presumably occurs through perturbed calcium channel function caused by the abnormal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#sca6.REF.chen.2007.c1078">Chen &#x00026; Piedras-Renteria 2007</a>, <a class="bk_pop" href="#sca6.REF.kordasiewicz.2007.285">Kordasiewicz &#x00026; Gomez 2007</a>].</p></div></dd><dt>6. </dt><dd><div id="sca6.TF.3.6"><p class="no_margin"><a class="bk_pop" href="#sca6.REF.yue.1997.1078">Yue et al [1997]</a>, <a class="bk_pop" href="#sca6.REF.tonelli.2006.13">Tonelli et al [2006]</a>, <a class="bk_pop" href="#sca6.REF.cricchi.2007.69">Cricchi et al [2007]</a></p></div></dd><dt>7. </dt><dd><div id="sca6.TF.3.7"><p class="no_margin">The two clinical forms of FMH are: (1) pure FHM (found in 80% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> families), in which interictal examination is normal in all family members, and (2) FHM with permanent cerebellar symptoms (found in 20% of affected families), in which some family members show interictal nystagmus and/or ataxia.</p></div></dd><dt>8. </dt><dd><div id="sca6.TF.3.8"><p class="no_margin">Trauma-triggered delayed cerebral edema has been associated with the <i>CACNA1A</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant p.Ser218Leu [<a class="bk_pop" href="#sca6.REF.kors.2001.753">Kors et al 2001</a>].</p></div></dd><dt>9. </dt><dd><div id="sca6.TF.3.9"><p class="no_margin"><a class="bk_pop" href="#sca6.REF.jen.1999.274">Jen [1999]</a></p></div></dd><dt>10. </dt><dd><div id="sca6.TF.3.10"><p class="no_margin"><a class="bk_pop" href="#sca6.REF.alonso.2003.610">Alonso et al [2003]</a></p></div></dd></dl></div></div></div><p>Heterozygous pathogenic variants in <i>CACNA1A</i> are also known to be associated with early-infantile epileptic encephalopathy (see OMIM <a href="https://omim.org/entry/617106" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617106</a>).</p></div><div id="sca6.Differential_Diagnosis"><h2 id="_sca6_Differential_Diagnosis_">Differential Diagnosis</h2><p>Individuals with spinocerebellar ataxia type 6 (SCA6) may present with unexplained ataxia that is part of the larger differential diagnosis of hereditary and acquired ataxias (see <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>).</p><p>It is difficult and often impossible to distinguish spinocerebellar ataxia type 6 (SCA6) from the other hereditary ataxias (see <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>). The differential diagnosis should also include <a href="/books/n/gene/parkinson-overview/">Parkinson disease</a> and acquired causes of cerebellar ataxia.</p><p>SCA6-related <i>CACNA1A</i> pathogenic variants should be in the differential diagnosis of adult-onset <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> progressive ataxia, multiple system atrophy (MSA).</p><div id="sca6.T.proportion_of_individuals_with_sc" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Proportion of Individuals with SCA6 Manifesting Phenotypic Features Compared with Individuals with SCA1, SCA3, and SCA2</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1140/table/sca6.T.proportion_of_individuals_with_sc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca6.T.proportion_of_individuals_with_sc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotypic Feature</th><th id="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SCA2</th><th id="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SCA1</th><th id="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SCA3</th><th id="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SCA6</th></tr></thead><tbody><tr><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cerebellar dysfunction</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr><tr><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reduced saccadic velocity</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">71%-92%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-6%</td></tr><tr><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myoclonus</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-40%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td></tr><tr><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystonia or chorea</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-38%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-25%</td></tr><tr><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pyramidal involvement</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">29%-31%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">33%-44%</td></tr><tr><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Peripheral neuropathy</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">44%-94%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16%-44%</td></tr><tr><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Intellectual impairment</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">31%-37%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%</td><td headers="hd_h_sca6.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Percentages modified from <a class="bk_pop" href="#sca6.REF.geschwind.1997a.1247">Geschwind et al [1997a]</a>, <a class="bk_pop" href="#sca6.REF.geschwind.1997b.842">Geschwind et al [1997b]</a>, <a class="bk_pop" href="#sca6.REF.sch_ls.1997a.924">Sch&#x000f6;ls et al [1997a]</a>, and <a class="bk_pop" href="#sca6.REF.sch_ls.1997b.1073">Sch&#x000f6;ls et al [1997b]</a></p></div></dd></dl></div></div></div></div><div id="sca6.Management"><h2 id="_sca6_Management_">Management</h2><div id="sca6.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with spinocerebellar ataxia type 6 (SCA6), the evaluations summarized in <a class="figpopup" href="/books/NBK1140/table/sca6.T.recommended_evaluations_following/?report=objectonly" target="object" rid-figpopup="figsca6Trecommendedevaluationsfollowing" rid-ob="figobsca6Trecommendedevaluationsfollowing">Table 5</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div id="sca6.T.recommended_evaluations_following" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with Spinocerebellar Ataxia Type 6</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1140/table/sca6.T.recommended_evaluations_following/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca6.T.recommended_evaluations_following_lrgtbl__"><table><thead><tr><th id="hd_h_sca6.T.recommended_evaluations_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_sca6.T.recommended_evaluations_following_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_sca6.T.recommended_evaluations_following_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic examination</td><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Incl annual use of rating scale to assess progression</td></tr><tr><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Brain MRI</td><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To evaluate extent of atrophy of cerebellum or other structures</td></tr><tr><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Videofluoroscopic swallow study</td><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To identify safest behaviors &#x00026; consistency of food least likely to trigger aspiration</td></tr><tr><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Physical therapy evaluation</td><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess risk of falling, determine whether assisted ambulation is necessary, &#x00026; advise regarding exercise</td></tr><tr><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ophthalmologic</b></td><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/ophthalmologist</td><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Family support/resources</td><td headers="hd_h_sca6.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Patients &#x00026; their families should be informed about natural history, treatment, <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>, genetic risks to other family members, &#x00026; consumer-oriented resources.</td></tr></tbody></table></div></div></div><div id="sca6.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management for individuals with SCA6 is supportive.</p><div id="sca6.T.treatment_of_manifestations_in_in" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Spinocerebellar Ataxia Type 6</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1140/table/sca6.T.treatment_of_manifestations_in_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca6.T.treatment_of_manifestations_in_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ataxia</b></td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acetazolamide</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May eliminate episodes of ataxia but does not delay or slow overall progression</td></tr><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Physical medicine &#x00026; rehabilitation / PT / OT</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Canes, walking sticks, &#x00026; walkers help prevent falling.</div></li><li class="half_rhythm"><div>Modification of home w/aids incl grab bars, raised toilet seats, &#x00026; ramps to accommodate motorized chairs may be necessary.</div></li><li class="half_rhythm"><div>Weighted eating utensils &#x00026; dressing hooks help maintain sense of independence.</div></li></ul>
</td></tr><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Regular physical activity</div></li><li class="half_rhythm"><div>PT &#x00026; exercises enhancing balance &#x00026; core strength</div></li></ul>
</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">However, neither exercise nor physical therapy stems progression of incoordination or muscle weakness.</td></tr><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Nutrition</b></td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vitamin supplements</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Particularly if caloric intake is reduced</td></tr><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Feeding recommendations per feeding therapist / OT</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Weight control</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Obesity can exacerbate difficulties w/ambulation &#x00026; mobility.</td></tr><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Vertigo/</b><br /><b>Osscilopsia</b></td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Diphenhydramine, baclofen, gabapentin</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>May reduce vertigo &#x00026;/or osscilopsia</div></li><li class="half_rhythm"><div>Some literature supports 4-aminopyridine for vestibular symptoms.&#x000a0;<sup>1</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Diplopia</b></td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Refractive or surgical management per ophthalmologist</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Some literature supports 4-aminopyridine for suppression of nystagmus.&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Dysarthria</b></td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Speech therapy</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Communication devices such as writing pads &#x00026; computer-based devices as needed</td></tr><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>REM sleep</b><br /><b>behavior</b><br /><b>disorders</b></td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clonazepam</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unless sedative effects increase imbalance in the morning</td></tr><tr><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Sleep apnea</b></td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Continuous positive airway pressure</td><td headers="hd_h_sca6.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">OT = occupational therapist/therapy; PT = physical therapist/therapy</p></div></dd><dt>1. </dt><dd><div id="sca6.TF.6.1"><p class="no_margin"><a class="bk_pop" href="#sca6.REF.jayabal.2016.29489">Jayabal et al [2016]</a></p></div></dd></dl></div></div></div></div><div id="sca6.Surveillance"><h3>Surveillance</h3><div id="sca6.T.recommended_surveillance_for_indi" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with Spinocerebellar Ataxia Type 6</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1140/table/sca6.T.recommended_surveillance_for_indi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca6.T.recommended_surveillance_for_indi_lrgtbl__"><table><thead><tr><th id="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ataxia</b></td><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic evaluation</td><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 6-12 mos</td></tr><tr><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Physiatrist &#x00026; physical &#x00026;/or occupational therapist consultations</td><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 12 mos to review need for walking aid(s) &#x00026; home adaptations</td></tr><tr><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Nutrition</b></td><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Nutrition evaluation</div></li><li class="half_rhythm"><div>Video esophagram</div></li><li class="half_rhythm"><div>Feeding assessment when dysphagia becomes troublesome</div></li></ul>
</td><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">As needed (e.g., w/any change in nutrition/feeding status)</td></tr><tr><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Diplopia</b></td><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation w/ophthalmologist &#x00026;/or optometrist for prisms or surgery</td><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">As needed (e.g., when other interventions fail)</td></tr><tr><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Assessment of driving ability by professional</td><td headers="hd_h_sca6.T.recommended_surveillance_for_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Periodically</td></tr></tbody></table></div></div></div><div id="sca6.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Agents with sedative/hypnotic properties such as ethanol or certain medications may produce marked increases in incoordination.</p></div><div id="sca6.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#sca6.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="sca6.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Although the disease rarely manifests during years of fertility, measures to support imbalance should be enhanced in symptomatic pregnant women.</p></div><div id="sca6.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p><a class="bk_pop" href="#sca6.REF.gazulla.2007.131">Gazulla &#x00026; Tintore [2007]</a> suggested gabapentin and pregabalin as potential therapeutic agents.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="sca6.Other"><h3>Other</h3><p>Tremor-controlling drugs are not usually effective in reducing cerebellar tremors.</p><p>The growing interest in cannabidiol (CBD) requires further empiric experience or clinical trials.</p></div></div><div id="sca6.Genetic_Counseling"><h2 id="_sca6_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="sca6.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Spinocerebellar ataxia type 6 (SCA6) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="sca6.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Because <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of SCA6 is 100%, most individuals diagnosed with SCA6 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with SCA6 may have the disorder as the result of an expansion of an intermediate or mutable normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> inherited from an unaffected parent [<a class="bk_pop" href="#sca6.REF.mariotti.2001.1502">Mariotti et al 2001</a>, <a class="bk_pop" href="#sca6.REF.shimazaki.2001.101">Shimazaki et al 2001</a>].</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of an individual with SCA6 and no known family history of SCA6 include clinical evaluation and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li><li class="half_rhythm"><div>Although most individuals diagnosed with SCA6 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of a proband depends on the genetic status of the parents:</p><ul><li class="half_rhythm"><div>If one parent has a full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> <i>CACNA1A</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, the risk to each sib of inheriting the pathogenic <i>CACNA1A</i> allele is 50%. Although the penetrance of SCA6 is nearly 100%, age of onset and clinical picture vary within families; sibs with the same size <a class="def" href="/books/n/gene/glossary/def-item/full-penetrance-allele/">full-penetrance allele</a> may differ in age of onset by as much as 12 years, or exhibit, at least initially, an episodic course (see <a href="#sca6.Clinical_Description">Clinical Description</a>).</div></li><li class="half_rhythm"><div>If one parent has an intermediate or mutable normal <i>CACNA1A</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (i.e., a 19-CAG repeat allele), the risk to each sib of inheriting the unstable allele is 50%. Further intergenerational expansion has been observed, but is extremely rare.</div></li><li class="half_rhythm"><div>If an expanded <i>CACNA1A</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li><li class="half_rhythm"><div>If the parents have not been tested for an expanded <i>CACNA1A</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> but are clinically unaffected, sibs are still presumed to be at increased risk for SCA6 because of the possibility of late onset of SCA6 in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent or the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with SCA6 has a 50% chance of inheriting the expanded <i>CACNA1A</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>Although repeat-size changes can occur in SCA6 alleles in subsequent generations, they are much rarer than those in other repeat expansion disorders.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has an SCA6-causing <i>CACNA1A</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, his or her family members may be at risk.</p></div><div id="sca6.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>At-risk individuals.</b> The age of onset, severity, specific symptoms, and progression of SCA6 are variable and cannot be predicted by the family history or results of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p><b>Predictive testing (i.e., testing of asymptomatic at-risk individuals)</b></p><ul><li class="half_rhythm"><div>Predictive testing for at-risk relatives is possible once <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has identified a <i>CACNA1A</i> CAG repeat expansion in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member.</div></li><li class="half_rhythm"><div>This testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals.</div></li><li class="half_rhythm"><div>Potential consequences of such testing (including but not limited to socioeconomic changes and the need for long-term follow-up and evaluation arrangements for individuals with a positive test result) as well as the capabilities and limitations of predictive testing should be discussed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> prior to testing.</div></li></ul><p><b>Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals age &#x0003c;18 years)</b></p><ul><li class="half_rhythm"><div>For asymptomatic minors at risk for adult-onset conditions for which early treatment would have no beneficial effect on disease morbidity and mortality, predictive genetic testing is considered inappropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</div></li><li class="half_rhythm"><div>For more information, see the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</div></li></ul><p>In a family with an established diagnosis of SCA6, it is appropriate to consider testing of symptomatic individuals regardless of age.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="sca6.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once a <i>CACNA1A</i> CAG repeat expansion has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> for SCA6 are possible. However, in general, age of onset, severity of disease, specific symptoms, and rate of disease progression are variable and cannot be accurately predicted by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="sca6.Resources"><h2 id="_sca6_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22234/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Spinocerebellar ataxia</a></div></li><li class="half_rhythm"><div><b>Spinocerebellar Ataxia: Making an Informed Choice about Genetic Testing</b></div><div><i>Booklet providing information about Spinocerebellar Ataxia</i></div><div><a href="http://depts.washington.edu/neurolog/images/neurogenetics/ataxia.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">depts.washington.edu/neurolog/images/neurogenetics/ataxia.pdf</a></div></li><li class="half_rhythm"><div><b>Ataxia UK</b></div><div>Lincoln House</div><div>1-3 Brixton Road</div><div>London SW9 6DE</div><div>United Kingdom</div><div><b>Phone:</b> 0845 644 0606 (helpline); 020 7582 1444 (office); +44 (0) 20 7582 1444 (from abroad)</div><div><b>Email:</b> helpline@ataxia.org.uk; office@ataxia.org.uk</div><div><a href="http://www.ataxia.org.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org.uk</a></div></li><li class="half_rhythm"><div><b>euro-ATAXIA (European Federation of Hereditary Ataxias)</b></div><div>Ataxia UK</div><div>Lincoln House, Kennington Park, 1-3 Brixton Road</div><div>London SW9 6DE</div><div>United Kingdom</div><div><b>Phone:</b> +44 (0) 207 582 1444</div><div><b>Email:</b> smillman@ataxia.org.uk</div><div><a href="https://www.euroataxia.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.euroataxia.org</a></div></li><li class="half_rhythm"><div><b>National Ataxia Foundation</b></div><div>2600 Fernbrook Lane</div><div>Suite 119</div><div>Minneapolis MN 55447</div><div><b>Phone:</b> 763-553-0020</div><div><b>Email:</b> naf@ataxia.org</div><div><a href="http://www.ataxia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org</a></div></li><li class="half_rhythm"><div><b>Spanish Ataxia Federation (FEDAES)</b></div><div>Spain</div><div><b>Phone:</b> 34 983 278 029; 34 985 097 152; 34 634 597 503</div><div><b>Email:</b> sede.valladolid@fedaes.org; sede.gijon@fedaes.org; sede.bilbao@fedaes.org</div><div><a href="http://www.fedaes.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fedaes.org</a></div></li><li class="half_rhythm"><div><b>CoRDS Registry</b></div><div>Sanford Research</div><div>2301 East 60th Street North</div><div>Sioux Falls SD 57104</div><div><b>Phone:</b> 605-312-6423</div><div><b>Email:</b> sanfordresearch@sanfordhealth.org</div><div><a href="http://www.sanfordresearch.org/SpecialPrograms/cords/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CoRDS Registry</a></div></li></ul></div><div id="sca6.Molecular_Genetics"><h2 id="_sca6_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="sca6.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Spinocerebellar Ataxia Type 6: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1140/table/sca6.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca6.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_sca6.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_sca6.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_sca6.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_sca6.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_sca6.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_sca6.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_sca6.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/773" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CACNA1A</i></a></td><td headers="hd_b_sca6.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=773" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19p13<wbr style="display:inline-block"></wbr>​.13</a></td><td headers="hd_b_sca6.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O00555" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Voltage-dependent P/Q-type calcium channel subunit alpha-1A</a></td><td headers="hd_b_sca6.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/CACNA1A" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (CACNA1A) @ LOVD</a></td><td headers="hd_b_sca6.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CACNA1A" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CACNA1A</a></td><td headers="hd_b_sca6.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CACNA1A[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CACNA1A</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="sca6.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="sca6.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Spinocerebellar Ataxia Type 6 (<a href="/omim/183086,601011" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1140/table/sca6.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca6.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/183086" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">183086</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPINOCEREBELLAR ATAXIA 6; SCA6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601011" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601011</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CALCIUM CHANNEL, VOLTAGE-DEPENDENT, P/Q TYPE, ALPHA-1A SUBUNIT; CACNA1A</td></tr></tbody></table></div></div><div id="sca6.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>CACNA1A</i> encodes two distinct protein <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>, an &#x003b1;1A subunit that serves as the pore-forming subunit of a voltage-dependent P/Q-type calcium channel (reviewed in <a class="bk_pop" href="#sca6.REF.greenberg.1997.275">Greenberg [1997]</a>), and a <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a>, &#x003b1;1ACT, which translocates to the nucleus and acts to enhance expression of several neuronally expressed genes [<a class="bk_pop" href="#sca6.REF.du.2013.118">Du et al 2013</a>]. Both &#x003b1;1A (some splice forms) and &#x003b1;1ACT bear the polymorphic CAG repeat that is expanded in spinocerebellar ataxia type 6 (SCA6).</p><p>P/Q-type calcium channels are high-voltage-activated calcium channels found primarily on neurons and expressed at high levels in granule cells and Purkinje cells of the cerebellar cortex. Their principal role is believed to be in synaptic transmission. &#x003b1;1A subunits are membrane glycoproteins approximately 2,400 amino acids in length that are the major pore-forming subunit of the P/Q-type voltage-gated calcium channel.</p><p>The discovery of the polymorphic CAG repeat in the 3' end <i>CACNA1A</i> was associated with the identification of a novel long splice form of the &#x003b1;1A <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> [<a class="bk_pop" href="#sca6.REF.zhuchenko.1997.62">Zhuchenko et al 1997</a>]. In the long splice form, inclusion of additional nucleotides at the end of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 46 eliminates a stop codon and places an additional 237 nucleotides of 3' sequence, including the polymorphic CAG repeat, in translational frame. The CAG repeat encodes a tract of glutamine residues, in which wild type alleles range from four to 18 glutamine residues in length.</p><p>The &#x003b1;1ACT protein is encoded as a separate protein within the 3' portion of the long splice form of &#x003b1;1A subunit <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>. The &#x003b1;1ACT polypeptide is translated from the &#x003b1;1A mRNA as a separate protein under the control of a cellular internal ribosomal entry site. &#x003b1;1ACT is a transcriptional protein that is translocated to nuclei and binds and enhances expression via a conserved AT-rich motif on several genes expressed in Purkinje cells. &#x003b1;1ACT expressed without &#x003b1;1A subunits accelerates neurite outgrowth in cultured neuronal cells and normalizes Purkinje cell dendrites and innervation when expressed in &#x003b1;1A knockout mice. &#x003b1;1ACT polypeptide bears the polymorphic polyglutamine tract [<a class="bk_pop" href="#sca6.REF.du.2013.118">Du et al 2013</a>, <a class="bk_pop" href="#sca6.REF.du.2019.770">Du et al 2019</a>].</p><p>The expanded CAG repeat in <i>CACNA1A</i> codes for an expanded polyglutamine tract present in the carboxy terminus of a long splice form of both the &#x003b1;1A subunit and the &#x003b1;1ACT protein [<a class="bk_pop" href="#sca6.REF.zhuchenko.1997.62">Zhuchenko et al 1997</a>].</p><p><b>Mechanism of disease causation.</b> While there is no consistent effect of the expanded polyglutamine tract on P/Q channel function, the polyqlutamine expansion alters <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> binding, impairs <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> function, and is toxic to cells expressing the &#x003b1;1ACT &#x02013; effects consistent with a loss of function.</p><p><b><i>CACNA1A</i>-specific laboratory technical considerations.</b> Specific nomenclature designations for DNA and protein variants of <i>SCA6</i>, and other repeat expansion disorders, can be found <a href="https://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">here</a>.</p></div></div><div id="sca6.References"><h2 id="_sca6_References_">References</h2><div id="sca6.Published_Guidelines__Consensus_Sta"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="sca6.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 11-15-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 11-15-19.</div></li></ul></div><div id="sca6.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.alonso.2003.610">Alonso I, Barros J, Tuna A, Coelho J, Sequeiros J, Silveira I, Coutinho P. Phenotypes of spinocerebellar ataxia type 6 and familial hemiplegic migraine caused by a unique CACNA1A missense mutation in patients from a large family. <span><span class="ref-journal">Arch Neurol. </span>2003;<span class="ref-vol">60</span>:610–4.</span> [<a href="/pubmed/12707077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12707077</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.baloh.1997.8">Baloh RW, Yue Q, Furman JM, Nelson SF. Familial episodic ataxia: clinical heterogeneity in four families linked to chromosome 19p. <span><span class="ref-journal">Ann Neurol. </span>1997;<span class="ref-vol">41</span>:8–16.</span> [<a href="/pubmed/9005860" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9005860</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.boesch.2006.529">Boesch SM, Frauscher B, Brandauer E, Wenning GK, Poewe W, H&#x000f6;gl B. Restless legs syndrome and motor activity during sleep in spinocerebellar ataxia type 6. <span><span class="ref-journal">Sleep Med. </span>2006;<span class="ref-vol">7</span>:529–32.</span> [<a href="/pubmed/16931150" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16931150</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.butteriss.2005.694">Butteriss D, Chinnery P, Birchall D. Radiological characterization of spinocerebellar ataxia type 6. <span><span class="ref-journal">Br J Radiol. </span>2005;<span class="ref-vol">78</span>:694–6.</span> [<a href="/pubmed/16046419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16046419</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.chen.2007.c1078">Chen H, Piedras-Renteria ES. Altered frequency-dependent inactivation and steady-state inactivation of polyglutamine-expanded alpha1A in SCA6. <span><span class="ref-journal">Am J Physiol Cell Physiol. </span>2007;<span class="ref-vol">292</span>:C1078–86.</span> [<a href="/pubmed/17020933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17020933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.craig.2004.752">Craig K, Keers SM, Archibald K, Curtis A, Chinnery PF. Molecular epidemiology of spinocerebellar ataxia type 6. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">55</span>:752–5.</span> [<a href="/pubmed/15122720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15122720</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.cricchi.2007.69">Cricchi F, Di Lorenzo C, Grieco GS, Rengo C, Cardinale A, Racaniello M, Santorelli FM, Nappi G, Pierelli F, Casali C. Early-onset progressive ataxia associated with the first CACNA1A mutation identified within the I-II loop. <span><span class="ref-journal">J Neurol Sci. </span>2007;<span class="ref-vol">254</span>:69–71.</span> [<a href="/pubmed/17292920" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17292920</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.du.2013.118">Du X, Wang J, Zhu H, Rinaldo L, Lamar K, Palmenberg AC, Hansel C, Gomez CM. Second cistron in <em>CACNA1A</em> gene encodes a transcription factor mediating cerebellar development and SCA6. <span><span class="ref-journal">Cell. </span>2013;<span class="ref-vol">154</span>:118–33.</span> [<a href="/pmc/articles/PMC3939801/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3939801</span></a>] [<a href="/pubmed/23827678" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23827678</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.du.2019.770">Du X, Wei C, Hejazi Pastor DP, Rao ER, Li Y, Grasselli G, Godfrey J, Palmenberg AC, Andrade J, Hansel C, Gomez CM. &#x003b1;1ACT is essential for survival and early cerebellar programming in a critical neonatal window. <span><span class="ref-journal">Neuron. </span>2019;<span class="ref-vol">102</span>:770–85.e7.</span> [<a href="/pmc/articles/PMC6533132/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6533132</span></a>] [<a href="/pubmed/30922876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30922876</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.gazulla.2007.131">Gazulla J, Tintore MA. The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit. <span><span class="ref-journal">Med Hypotheses. </span>2007;<span class="ref-vol">68</span>:131–6.</span> [<a href="/pubmed/16899342" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16899342</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.geschwind.1997a.1247">Geschwind DH, Perlman S, Figueroa KP, Karrim J, Baloh RW, Pulst SM. Spinocerebellar ataxia type 6. Frequency of the mutation and genotype-phenotype correlations. <span><span class="ref-journal">Neurology. </span>1997a;<span class="ref-vol">49</span>:1247–51.</span> [<a href="/pubmed/9371902" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9371902</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.geschwind.1997b.842">Geschwind DH, Perlman S, Figueroa CP, Treiman LJ, Pulst SM. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. <span><span class="ref-journal">Am J Hum Genet. </span>1997b;<span class="ref-vol">60</span>:842–50.</span> [<a href="/pmc/articles/PMC1712476/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1712476</span></a>] [<a href="/pubmed/9106530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9106530</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.globas.2003.1482">Globas C, Bosch S, Zuhlke Ch, Daum I, Dichgans J, Burk K. The cerebellum and cognition. Intellectual function in spinocerebellar ataxia type 6 (SCA6). <span><span class="ref-journal">J Neurol. </span>2003;<span class="ref-vol">250</span>:1482–7.</span> [<a href="/pubmed/14673583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14673583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.gomez.1997.933">Gomez CM, Thompson RM, Gammack JT, Perlman SL, Dobyns WB, Truwit CL, Zee DS, Clark HB, Anderson JH. Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. <span><span class="ref-journal">Ann Neurol. </span>1997;<span class="ref-vol">42</span>:933–50.</span> [<a href="/pubmed/9403487" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9403487</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.greenberg.1997.275">Greenberg DA. Calcium channels in neurological disease. <span><span class="ref-journal">Ann Neurol. </span>1997;<span class="ref-vol">42</span>:275–82.</span> [<a href="/pubmed/9307247" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9307247</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.hashimoto.2003.1201">Hashimoto T, Sasaki O, Yoshida K, Takei Y, Ikeda S. Periodic alternating nystagmus and rebound nystagmus in spinocerebellar ataxia type 6. <span><span class="ref-journal">Mov Disord. </span>2003;<span class="ref-vol">18</span>:1201–4.</span> [<a href="/pubmed/14534930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14534930</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.howell.2006.1430">Howell MJ, Mahowald MW, Gomez CM. Evaluation of sleep and daytime somnolence in spinocerebellar ataxia type 6 (SCA6). <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">66</span>:1430–1.</span> [<a href="/pubmed/16682680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16682680</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.ikeuchi.1997.879">Ikeuchi T, Takano H, Koide R, Horikawa Y, Honma Y, Onishi Y, Igarashi S, Tanaka H, Nakao N, Sahashi K, Tsukagoshi H, Inoue K, Takahashi H, Tsuji S. Spinocerebellar ataxia type 6: CAG repeat expansion in alpha1A voltage- dependent calcium channel gene and clinical variations in Japanese population. <span><span class="ref-journal">Ann Neurol. </span>1997;<span class="ref-vol">42</span>:879–84.</span> [<a href="/pubmed/9403480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9403480</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.ishikawa.1997.336">Ishikawa K, Tanaka H, Saito M, Ohkoshi N, Fujita T, Yoshizawa K, Ikeuchi T, Watanabe M, Hayashi A, Takiyama Y, Nishizawa M, Nakano I, Matsubayashi K, Miwa M, Shoji S, Kanazawa I, Tsuji S, Mizusawa H. Japanese families with autosomal dominant pure cerebellar ataxia map to chromosome 19p13.1-p13.2 and are strongly associated with mild CAG expansions in the spinocerebellar ataxia type 6 gene in chromosome 19p13.1. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">61</span>:336–46.</span> [<a href="/pmc/articles/PMC1715894/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1715894</span></a>] [<a href="/pubmed/9311738" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9311738</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.jayabal.2016.29489">Jayabal S, Chang HH, Cullen KE, Watt AJ. 4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6. <span><span class="ref-journal">Sci Rep. </span>2016;<span class="ref-vol">6</span>:29489.</span> [<a href="/pmc/articles/PMC4933933/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4933933</span></a>] [<a href="/pubmed/27381005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27381005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.jen.1999.274">Jen J. Calcium channelopathies in the central nervous system. <span><span class="ref-journal">Curr Opin Neurobiol. </span>1999;<span class="ref-vol">9</span>:274–80.</span> [<a href="/pubmed/10395579" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10395579</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.jiang.2005.25">Jiang H, Tang B, Xia K, Zhou Y, Xu B, Zhao G, Li H, Shen L, Pan Q, Cai F. Spinocerebellar ataxia type 6 in Mainland China: molecular and clinical features in four families. <span><span class="ref-journal">J Neurol Sci. </span>2005;<span class="ref-vol">236</span>:25–9.</span> [<a href="/pubmed/15979648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15979648</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.jodice.1997.1973">Jodice C, Mantuano E, Veneziano L, Trettel F, Sabbadini G, Calandriello L, Francia A, Spadaro M, Pierelli F, Salvi F, Ophoff RA, Frants RR, Frontali M. Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. <span><span class="ref-journal">Hum Mol Genet. </span>1997;<span class="ref-vol">6</span>:1973–8.</span> [<a href="/pubmed/9302278" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9302278</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.katayama.2000.711">Katayama T, Ogura Y, Aizawa H, Kuroda H, Suzuki Y, Kuroda K, Kikuchi K. Nineteen CAG repeats of the SCA6 gene in a Japanese patient presenting with ataxia. <span><span class="ref-journal">J Neurol. </span>2000;<span class="ref-vol">247</span>:711–2.</span> [<a href="/pubmed/11081813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11081813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.kordasiewicz.2007.285">Kordasiewicz HB, Gomez CM. Molecular pathogenesis of spinocerebellar ataxia type 6. <span><span class="ref-journal">Neurotherapeutics. </span>2007;<span class="ref-vol">4</span>:285–94.</span> [<a href="/pubmed/17395139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17395139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.kors.2001.753">Kors EE, Terwindt GM, Vermeulen FL, Fitzsimons RB, Jardine PE, Heywood P, Love S, van den Maagdenberg AM, Haan J, Frants RR, Ferrari MD. Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. <span><span class="ref-journal">Ann Neurol. </span>2001;<span class="ref-vol">49</span>:753–60.</span> [<a href="/pubmed/11409427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11409427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.lukas.2011.123">Lukas C, Bellenberg B, K&#x000f6;ster O, Greschner S, Hahn HK. A new sulcus-corrected approach for assessing cerebellar volume in spinocerebellar ataxia. <span><span class="ref-journal">Psychiatry Res. </span>2011;<span class="ref-vol">193</span>:123–30.</span> [<a href="/pubmed/21680158" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21680158</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.mariotti.2001.1502">Mariotti C, Gellera C, Grisoli M, Mineri R, Castucci A, Di Donato S. Pathogenic effect of an intermediate-size SCA-6 allele (CAG)(19) in a homozygous patient. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">57</span>:1502–4.</span> [<a href="/pubmed/11673601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11673601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.matsumura.1997.1238">Matsumura R, Futamura N, Fujimoto Y, Yanagimoto S, Horikawa H, Suzumura A, Takayanagi T. Spinocerebellar ataxia type 6. Molecular and clinical features of 35 Japanese patients including one homozygous for the CAG repeat expansion. <span><span class="ref-journal">Neurology. </span>1997;<span class="ref-vol">49</span>:1238–43.</span> [<a href="/pubmed/9371900" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9371900</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.matsuyama.1997.1283">Matsuyama Z, Kawakami H, Maruyama H, Izumi Y, Komure O, Udaka F, Kameyama M, Nishio T, Kuroda Y, Nishimura M, Nakamura S. Molecular features of the CAG repeats of spinocerebellar ataxia 6 (SCA6). <span><span class="ref-journal">Hum Mol Genet. </span>1997;<span class="ref-vol">6</span>:1283–7.</span> [<a href="/pubmed/9259274" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9259274</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.moscovich.2015.16">Moscovich M, Okun MS, Favilla C, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai V, Ying S, Zesiewicz T, Kuo SH, Mazzoni P, Bushara K, Xia G, Ashizawa T, Subramony SH. Clinical evaluation of eye movements in spinocerebellar ataxias: a prospective multicenter study. <span><span class="ref-journal">J Neuroophthalmol. </span>2015;<span class="ref-vol">35</span>:16–21.</span> [<a href="/pmc/articles/PMC4675453/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4675453</span></a>] [<a href="/pubmed/25259863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25259863</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.pujana.1999.516">Pujana MA, Corral J, Gratacos M, Combarros O, Berciano J, Genis D, Banchs I, Estivill X, Volpini V. Spinocerebellar ataxias in Spanish patients: genetic analysis of familial and sporadic cases. The Ataxia Study Group. <span><span class="ref-journal">Hum Genet. </span>1999;<span class="ref-vol">104</span>:516–22.</span> [<a href="/pubmed/10453742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10453742</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.riess.1997.1289">Riess O, Sch&#x000f6;ls L, Bottger H, Nolte D, Vieira-Saecker AM, Schimming C, Kreuz F, Macek M Jr, Krebsova A, Macek M, Sen, Klockgether T, Zuhlke C, Laccone FA. SCA6 is caused by moderate CAG expansion in the alpha1A-voltage- dependent calcium channel gene. <span><span class="ref-journal">Hum Mol Genet. </span>1997;<span class="ref-vol">6</span>:1289–93.</span> [<a href="/pubmed/9259275" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9259275</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.sasaki.1998.199">Sasaki H, Kojima H, Yabe I, Tashiro K, Hamada T, Sawa H, Hiraga H, Nagashima K. Neuropathological and molecular studies of spinocerebellar ataxia type 6 (SCA6). <span><span class="ref-journal">Acta Neuropathol (Berl). </span>1998;<span class="ref-vol">95</span>:199–204.</span> [<a href="/pubmed/9498057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9498057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.sch_ls.1997a.924">Sch&#x000f6;ls L, Amoiridis G, B&#x000fc;ttner T, Przuntek H, Epplen JT, Riess O. Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? <span><span class="ref-journal">Ann Neurol. </span>1997a;<span class="ref-vol">42</span>:924–32.</span> [<a href="/pubmed/9403486" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9403486</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.sch_ls.1997b.1073">Sch&#x000f6;ls L, Gispert S, Vorgerd M, Menezes Vieira-Saecker AM, Blanke P, Auburger G, Amoiridis G, Meves S, Epplen JT, Przuntek H, Pulst SM, Riess O. Spinocerebellar ataxia type 2. Genotype and phenotype in German kindreds. <span><span class="ref-journal">Arch Neurol. </span>1997b;<span class="ref-vol">54</span>:1073–80.</span> [<a href="/pubmed/9311350" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9311350</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.sch_ls.1998.67">Sch&#x000f6;ls L, Kr&#x000fc;ger R, Amoiridis G, Przuntek H, Epplen JT, Riess O. Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1998;<span class="ref-vol">64</span>:67–73.</span> [<a href="/pmc/articles/PMC2169927/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2169927</span></a>] [<a href="/pubmed/9436730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9436730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.shimazaki.2001.101">Shimazaki H, Takiyama Y, Sakoe K, Amaike M, Nagaki H, Namekawa M, Sasaki H, Nakano I, Nishizawa M. Meiotic instability of the CAG repeats in the SCA6/CACNA1A gene in two Japanese SCA6 families. <span><span class="ref-journal">J Neurol Sci. </span>2001;<span class="ref-vol">185</span>:101–7.</span> [<a href="/pubmed/11311290" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11311290</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.shizuka.1998.85">Shizuka M, Watanabe M, Ikeda Y, Mizushima K, Okamoto K, Shoji M. Molecular analysis of a de novo mutation for spinocerebellar ataxia type 6 and (CAG)n repeat units in normal elder controls. <span><span class="ref-journal">J Neurol Sci. </span>1998;<span class="ref-vol">161</span>:85–7.</span> [<a href="/pubmed/9879686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9879686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.stevanin.1997.1243">Stevanin G, D&#x000fc;rr A, David G, Didierjean O, Cancel G, Rivaud S, Tourbah A, Warter JM, Agid Y, Brice A. Clinical and molecular features of spinocerebellar ataxia type 6. <span><span class="ref-journal">Neurology. </span>1997;<span class="ref-vol">49</span>:1243–6.</span> [<a href="/pubmed/9371901" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9371901</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.takahashi.2004.256">Takahashi H, Ishikawa K, Tsutsumi T, Fujigasaki H, Kawata A, Okiyama R, Fujita T, Yoshizawa K, Yamaguchi S, Tomiyasu H, Yoshii F, Mitani K, Shimizu N, Yamazaki M, Miyamoto T, Orimo T, Shoji S, Kitamura K, Mizusawa H. A clinical and genetic study in a large cohort of patients with spinocerebellar ataxia type 6. <span><span class="ref-journal">J Hum Genet. </span>2004;<span class="ref-vol">49</span>:256–64.</span> [<a href="/pubmed/15362569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15362569</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.tonelli.2006.13">Tonelli A, D'Angelo MG, Salati R, Villa L, Germinasi C, Frattini T, Meola G, Turconi AC, Bresolin N, Bassi MT. Early onset, non-fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene. <span><span class="ref-journal">J Neurol Sci. </span>2006;<span class="ref-vol">241</span>:13–7.</span> [<a href="/pubmed/16325861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16325861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.yabe.1998.89">Yabe I, Sasaki H, Matsuura T, Takada A, Wakisaka A, Suzuki Y, Fukazawa T, Hamada T, Oda T, Ohnishi A, Tashiro K. SCA6 mutation analysis in a large cohort of the Japanese patients with late-onset pure cerebellar ataxia. <span><span class="ref-journal">J Neurol Sci. </span>1998;<span class="ref-vol">156</span>:89–95.</span> [<a href="/pubmed/9559993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9559993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.yabe.2003.440">Yabe I, Sasaki H, Takeichi N, Takei A, Hamada T, Fukushima K, Tashiro K. Positional vertigo and macroscopic downbeat positioning nystagmus in spinocerebellar ataxia type 6 (SCA6). <span><span class="ref-journal">J Neurol. </span>2003;<span class="ref-vol">250</span>:440–3.</span> [<a href="/pubmed/12700909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12700909</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.yue.1997.1078">Yue Q, Jen JC, Nelson SF, Baloh RW. Progressive ataxia due to a missense mutation in a calcium-channel gene. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">61</span>:1078–87.</span> [<a href="/pmc/articles/PMC1716037/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1716037</span></a>] [<a href="/pubmed/9345107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9345107</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca6.REF.zhuchenko.1997.62">Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. <span><span class="ref-journal">Nat Genet. </span>1997;<span class="ref-vol">15</span>:62–9.</span> [<a href="/pubmed/8988170" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8988170</span></a>]</div></li></ul></div></div><div id="sca6.Chapter_Notes"><h2 id="_sca6_Chapter_Notes_">Chapter Notes</h2><div id="sca6.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>21 November 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 July 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 June 2008 (cd) Revision: mutation scanning/<a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> no longer available clinically</div></li><li class="half_rhythm"><div>21 September 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 January 2007 (cd) Revision: errata, Genotype-Phenotype Correlations, Heterozygous individuals</div></li><li class="half_rhythm"><div>12 May 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 April 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 July 2000 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 October 1998 (pb) Review posted live</div></li><li class="half_rhythm"><div>7 April 1998 (cg) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1140</span><span class="label">PMID: <a href="/pubmed/20301319" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301319</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sca3/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sca7/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1140&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1140/?report=reader">PubReader</a></li><li><a href="/books/NBK1140/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1140" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1140" style="display:none" title="Cite this Page"><div class="bk_tt">Casey HL, Gomez CM. Spinocerebellar Ataxia Type 6. 1998 Oct 23 [Updated 2019 Nov 21]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1140/pdf/Bookshelf_NBK1140.pdf">PDF version of this page</a> (475K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#sca6.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#sca6.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#sca6.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#sca6.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#sca6.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#sca6.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#sca6.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#sca6.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#sca6.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#sca6.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#sca6.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=773[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CACNA1A</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1482986" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1482986" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1482986" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1482986" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301363" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Opal P, Ashizawa T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301375" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 3</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 3<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Paulson H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301445" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 8</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 8<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ayhan F, Ikeda Y, Dalton JC, Day JW, Ranum LPW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301354" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 10</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 10<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Matsuura T, Ashizawa T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301452" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 2</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 2<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pulst SM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301319" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301319" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04104b75f66d18aace7439">Spinocerebellar Ataxia Type 6 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Spinocerebellar Ataxia Type 6 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:43:39-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8B8FB8E04104310000000000030001&amp;ncbi_session=CE8B8FB8E0410491_0003SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1140%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1140&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1140/&amp;ncbi_pagename=Spinocerebellar Ataxia Type 6 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B8FB8E0410491_0003SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>